Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.
Wiktoria Pałka, Paweł Moćko, Katarzyna Śladowska et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis evaluated the efficacy and safety of liraglutide, semaglutide, and tirzepatide in adults with a BMI ≥ 25 kg/m² over a duration of at least 52 weeks. The analysis included 24 randomized controlled trials, revealing that tirzepatide 15 mg was the most effective for weight and waist reduction, while semaglutide 7.2 mg showed a modest incremental benefit over 2.4 mg, particularly in the diabetes subgroup.
Key findings
- Tirzepatide 15 mg ranked highest for weight and waist reduction based on P-scores.
- Semaglutide 7.2 mg showed a significant advantage in percentage body weight change only in the diabetes subgroup.
- Liraglutide 3.0 mg resulted in the smallest weight loss among the treatments.
- No significant differences in serious adverse events were observed between treatments.
Why it matters
Understanding the comparative efficacy and safety of these GLP-1 receptor agonists is crucial for clinicians in managing overweight and obesity, particularly in selecting appropriate pharmacotherapy based on patient needs and preferences.